App-Quantinova.ai

Post‐transplant outcomes of children with primary haemophagocytic lymphohistiocytosis given emapalumab to control disease

M. B. Jordan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophagocytic lymphohistiocytosis

Dexamethasone

The long‐term quality of life impact of vincristine neurotoxicity in paediatric acute lymphoblastic leukaemia survivors – a retrospective cohort study

C. Horgan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral neuropathy

Vincristine

Clinical outcomes following autologous haematopoietic stem cell transplantation with LentiGlobin gene therapy in the phase 3 Northstar‐2 and Northstar‐3 studies for transfusion‐dependent β‐thalassaemia

J. B. Porter - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Transfusion‐dependent β‐thalassaemia

Defibrotide

Analysis of second line treatments for children with persistent or chronic primary immune thrombocytopenia (ITP) in the UK

B. Chaudhury - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Rituximab

Updated results from the single‐arm, open‐label, long‐term efficacy and safety study of subcutaneous (SC) romiplostim in children with immune thrombocytopenia (ITP)

J. Grainger - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

Romiplostim

A novel assay of neutrophil extracellular traps (NETs) formation independently predicts DIC and identifies the rationale for anti‐IL‐8 therapies

S. Abrams - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Disseminated intravascular coagulation

Interleukin

Gain of function variant of prothrombin (p.R541W) causes dominant heritable thrombosis and is associated with antithrombin resistance

S. Sivapalaratnam - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

Protein C

When is immune thrombocytopenia not immune thrombocytopenia? Using high‐throughput sequencing to distinguish patients with inherited thrombocytopenia and diseases of immune dysregulation

N. Joshi - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Immune thrombocytopenia

N/A

Molecular dynamics analysis provides mechanistic insights into ACTN1‐related thrombocytopenia

S. Westbury - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Macrothrombocytopenia

N/A

Why separate the inseparable? Integrating Mind and Body Care in haematology

Michelle Kenyon - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Hematology-oncology disease

Albert

Whole genome profiling of adult B‐other acute lymphoblastic leukaemia on the UKALL14 trial

D. Leongamornlert - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Seizures, scoliosis, and macrocephaly syndrome

N/A

Regulation of acute myeloid leukaemia maintenance by Wilms tumour 1 in an isoform specific manner

S. Potluri - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Doxycycline

BCAT1 increases sensitivity to Cytarabine and confers CXXC motif derived resistance to pro‐oxidant treatment in Acute Myeloid Leukaemia cells

J. Hillier - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Cytarabine liposomal

Towards clinical whole genome sequencing (WGS) in acute leukaemias – learning from the 100 000 Genomes Project

A. Sosinsky - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute Leukemia

Methadone hydrochloride

Targeting SET‐PP2A complex as a new avenue of treatment for Mixed Lineage Leukemia (MLL) treatment

A. Di Mambro - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

FTY720

Therapeutic potential of allogeneic gamma delta T cell therapy in relapsed/refractory acute myeloid leukaemia – preliminary data from a phase 1 study

J. Vydra - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

Cyclophosphamide

Efficacy of FMS‐like Tyrosine Kinase 3 (FLT3) inhibitors in patients with acute myeloid leukemia

T. W. Htut - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

gilteritinib

Combination therapies targeting apoptosis pathways in paediatric AML

A. Ali - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

LY-2409881

Combination therapies targeting DNA damage signalling as a therapeutic strategy in acute myeloid leukaemia

L. Monaghan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

ribose

Use of next generation sequencing to identify AML with germline predisposition; an essential diagnostic test

A. Duguid - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute myelocytic leukemia

Cytarabine liposomal

Filters

45280 Abstracts